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Expression proﬁleBackground: Prognosis associated with metastatic renal cell carcinoma (mRCC) can vary widely.
Methods: This study used pretreatment nephrectomy specimens from a randomized phase III trial. Expression
levels of candidate genes were determined from archival tumors using the OpenArray® platform for TaqMan®
RT-qPCR. The dataset was randomly divided at 2:1 ratio into training (n = 221) and testing (n = 103) sets to
develop a multigene prognostic signature.
Findings:Gene expressionsweremeasured in 324patients. In the training set,multiplemodels testing 424 candidate
genes identiﬁed aprognostic signature containing8 genes plusMSKCC clinical risk factors. In the testing set, the time
dependent (td) AUC for a prognostic model containing the 8 genes with and without MSKCC risk factors were 0.72
and0.69, respectively. The tdAUC for the clinical risk factors alonewas 0.61. Additional primarymRCCs frompatients
with mRCC (n = 12) were sampled in multiple sites and standard deviations of gene expressions within a tumor
were used as ameasure of heterogeneity. All 8 genes in the ﬁnal prognosticmodelmet our criteria forminimal het-
erogeneity.
Conclusions:Amolecular prognostic signature basedon8 geneswasdeveloped and is ready for external validation in
this patient population and other related settings such as nonmetastatic RCC.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite being uniformly fatal, survival associated with metastatic
renal cell carcinoma (RCC) can vary widely, from a few months to
several years. While clinical ﬁndings and histomorphologic characteris-
tics of the tumor can provide reasonable estimates of survival, greater
precision is needed. Whether molecular signatures from the primary
tumor can provide that increased precision is not known, but if so, this
approachmight prove useful for patient counseling, treatment planning,
and determining clinical trial eligibility.er, 8700 Beverly Boulevard, Los
this work.
. This is an open access article underMany prior studies have reported biomarkers and molecular signa-
tures for predicting survival (Takahashi et al., 2001; Sultmann et al.,
2005; Kosari et al., 2005; Jones et al., 2005; Zhao et al., 2006; Cancer
Genome Atlas Research N, 2013; Brannon et al., 2010). Unfortunately,
the majority of these studies included patients with both localized and
metastatic RCC. Most localized RCCs have a favorable prognosis, and the
American Urologic Association recommends observation as a valid man-
agement formany small renal cancers (Campbell et al., 2009). In contrast,
metastatic RCC is nearly always fatal. Therefore, it is not surprising that
molecular signatures can be readily identiﬁed for separating these pa-
tients into two prognostic groups. In contrast, there is a paucity of studies
reporting prognostic molecular signatures that can be applied solely to
metastatic RCC.
Prior studies of biomarkers fromcytoreductive nephrectomies are also
limited by small sample sizes and have usually focused on a limitedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(Vasselli et al., 2003; Miyake et al., 2009; Kusuda et al., 2013; Kim et al.,
2005). To develop prognostic biomarkers for metastatic RCC, there re-
mains a need for discovery studies using multi-institutional tissue banks
from well-characterized patients whose treatment and outcomes were
rigorously annotated. Therefore,we report a gene expression-based prog-
nostic signature developed using primary untreated RCC collected as part
of Cancer and Leukemia Group B (CALGB) 90206, a randomized phase III
trial of interferon alpha (INF) vs. INF plus bevacizumab in patients with
metastatic or unresectable RCC (Rini et al., 2010). CALGB is now a part
of the Alliance for Clinical Trials in Oncology. CALGB 90206 demonstrated
statistically longer progression-free survival (PFS) but no statistical over-
all survival (OS) beneﬁt for patients treated with the combination thera-
py. CALGB 90206 was used to develop a prognostic signature for
predicting OS.
2. Materials and Methods
2.1. Patient Population
Patients eligible for CALGB 90206 had metastatic or unresectable RCC
with a clear cell histology, Karnofsky performance status ≥70%, and ade-
quate organ function. Prior chemotherapy for metastatic disease was
not permitted. A stratiﬁed random block design was used with the strat-
iﬁcation factors of nephrectomy and number of adverse risk factors as de-
ﬁned by theMotzer criteria (Motzer et al., 2002). All details of the clinical
trial are published elsewhere (Rini et al., 2008, 2010). Each participant
signed an IRB-approved, protocol-speciﬁc informed consent in accor-
dancewith federal and institutional guidelines. Data collection and statis-
tical analyses were conducted by the Alliance Statistics and Data Center.
2.2. RNA Extraction
Using tumors received as part of CALGB 90206, H&E stains were
made of samples received by CALGB and were reviewed by a genitouri-
nary pathologist (JS)whoannotated the outline of the tumor on a digital
image, which was used to macrodissect the tumor for RNA extraction.
All assay work was performed at Cedars Sinai (HK). Our method for
RNA extraction from FFPE renal tumors has been previously described
(Glenn et al., 2010). Brieﬂy, RNAwas extracted from six 10-μm sections
when archival blocks were available. Some participating sites chose to
send unstained slides, and three 5-μm sections were used.
Tumor sections were placed in 2.0-ml RNase-free Eppendorf tubes.
Sections were treated twice with 1.9 ml xylene for 5 min (min) at
55 °C while rocking. The sections were washed twice with 100% etha-
nol. RNA was extracted from the parafﬁn samples using the
MasterPure™ RNA Puriﬁcation Kit (Epicenter Biotechnologies, Madi-
son,WI, USA). In an attempt to further increase RNA yield, FFPE samples
were treated with 200 μg Proteinase K for 3 h at 55 °C. RNA was then
treated with 20 units DNase I (Ambion, Austin, TX, USA) for 30 min
and checked for residual genomic DNA by TaqMan RT-PCR targeting
ACTB. If there was measurable DNA after 34 PCR cycles using 50 ng
input RNA, the samples were treated with 20 units DNase I for an addi-
tional 15 min, and the assay for residual DNA was repeated. The ﬁnal
RNA concentration (A260:0.025) and purity (A260:A280 ratio) was
measured using a NanoDrop ND-2000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA).
2.3. Reverse Transcription
Reverse transcription (RT) was performed using the High Capacity
cDNA Reverse Transcription Kit (Life Technologies, Grand Island, NY)
following the manufacturer's recommendation. Each 10 μl RT reaction
contained 150 ng of total RNA (75 ng or 37.5 ng was used for cases
with lower RNA yield), 1 μl of 10X RT buffer, 0.5 μl of 25X dNTPmixture,
1 μl of 10X random reverse primers, 1 μl of 10X gene-speciﬁc reverseprimers (1 μM) and 0.5 μl ofMultiScribe RT (50U/μl). The 10 μl reactions
were incubated in a Life Technologies Thermocycler for 10min at 25 °C,
2 h at 37 °C, 5 min at 85 °C and then held at 4 °C. 10X pooled gene-
speciﬁc reverse primers (1 μM)were prepared by combining equal vol-
umes of each 500 μM reverse primer (primers for all candidate genes
were pooled). The same primers were used for gene-speciﬁc RT,
preampliﬁcation and qPCR. The candidate genes were identiﬁed from
a literature search for prognostic and predictive gene expressions deter-
mined from microarrays and tissue microarrays. Key genes involved in
pathways known to be important in RCC were also included.
The preampliﬁcation was performed using TaqMan® PreAmp Mas-
terMix Kit (Life Technologies, Grand Island, NY) as previously described
(Li et al., 2013). Each 5 μl of preampliﬁcation reaction included 2.5 μl of
2X TaqMan®PreAmpMasterMix, 1.25 μl of 0.09Xpooled TaqMan assay
mix and 1.25 μl of cDNA. The reactions were incubated in an Applied
Biosystems Thermocycler for 10 min at 95 °C followed by 13–15 cycles
(depending on starting RNA) of 95 °C for 15 s and 60 °C for 4 min and
then held at 4 °C. Pooled TaqMan assays (0.09X)were prepared by com-
bining equal volumes of each 20X TaqMan assay (needed for PCR on the
Openarray®, 218 assays for each set). Each cDNA was preampliﬁed on
two sets of 218 pooled assays. Preampliﬁed cDNAproductswere diluted
10 times with 1X TE buffer for storage and PCR.
2.4. Real-time PCR on OpenArray Platform
Two sets of TaqMan® OpenArray® Real-Time PCR Plates (Life Tech-
nologies, Grand Island, NY) were made using custom-designed primers
and probes. Our strategy for designing TaqMan® assays has been de-
scribed (Li et al., 2013). Brieﬂy, gene sequences were downloaded
from GenBank (http://www.ncbi.nlm.nih.gov/genbank/). Repeats and
low complexity sequences, and SNPs were masked. The resulting se-
quences were sent to Life Technologies for custom design of primers
and probes using their proprietary software. Each PCR target was blast-
ed to avoid ampliﬁcation of unintended targets. When multiple iso-
forms existed, targets were selected in regions common to all
isoforms. All primers were designed to generate amplicons less than
100 base pairs (Supplemental Table 1).
Each OpenArray® Real-Time PCR Plate contains 218 TaqMan® as-
says. Diluted preampliﬁed cDNA (10 μl) was mixed with 10 μl of
TaqMan® OpenArray® Real-Time PCR Master Mix (Life Technologies,
Grand Island, NY). The mixed cDNA samples were dispensed into an
OpenArray® 384-well Sample Plate (Life Technologies, Grand Island,
NY)with each sample placed into 4wells at 5 μl per well. cDNA samples
were then dispensed into OpenArray® Real-Time PCR Plates using
OpenArray® AccuFill™ System (Life Technologies, Grand Island, NY).
The real-time PCR reactions were incubated in an OpenArray® NT Cy-
cler system for 2 min at 50 °C, 10 min at 95 °C followed by 40 cycles
of 95 °C for 15 s and 60 °C for 1 min and then held at 4 °C.
Post-acquisition data processing generated ﬂuorescence ampliﬁca-
tion for each assay, from which cycle threshold (CT) were computed
and used for further data analysis. Each gene was normalized using 6
previously identiﬁed reference genes, whichweremeasured in quadru-
plicate (Glenn et al., 2007). Each PCRplate had a control cDNAand ACTB
ampliﬁcation was always with 0.5 CT of the expected value. Tumor ex-
pression data were generated for 430 candidate genes identiﬁed from a
literature search. CT levels were normalized with six housekeeping
genes. Expression levels that were too low to detect were imputed to
30, which corresponded to a single copy of a gene in the assay chamber
(Li et al., 2013).
2.5. Statistical Analysis
The primary end point used for this analysis was overall survival (OS),
deﬁned as the time from randomization to date of death of any cause. The
date of data cutoff for the clinical trial was March 24, 2009 and median
followup among surviving patients was 46.2 months. The dataset was
Fig. 1. REMARK diagram. The diagram accounts for each patient in the parent clinical trial
and the availability of their tumor tissue for this study.
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103) sets to develop a multigene prognostic signature. Training and test-
ing samples were normalized together prior to random allocation. To ad-
just for any lingering batch effects, we calculated gene means and
standard deviations within each batch, then centered and scaled samples
to have within-batch gene means 0 and standard deviations 1. The com-
parative CT method was used to analyze the data (also referred to as
ΔΔCT) (Schmittgen and Livak, 2008).
There were 12 individuals with two samples from different regions
of the tumor that were used to assess heterogeneity.We used themedi-
an of the 12 standard deviations as a measure of stability and chose a
cut-point of 0.78. K-means clustering algorithm was utilized to identify
the threshold for the stable genes.
2.6. Model Building
Several stepswere used formodel building to help prioritize genes for
the multivariable model of OS. First, univariate proportional hazards
models were ﬁt in the training set to test for the prognostic importance
of the 424 genes in predicting overall survival. Twenty-one genes had
q-value (false discovery rate) b0.05 in the univariate scans and were se-
lected for the multivariable model. In the second step, the least absolute
shrinkage and selection operator (LASSO) penalty was used to identify
important genes for the multivariable model (Tibshirani, 1997). The
main advantage of using penalized methods is that they produce sparse
regression coefﬁcients, and the selection of important prognostic factors
does not depend on statistical signiﬁcance. The regularization parameter
was chosen to minimize the Schwarz Information Criterion. The 95% CI
for the LASSO was derived by adopting the perturbation method pro-
posed by Minnier and extending their work to the Cox's regression
(Minnier et al., 2011; Lin andHalabi, in press). In theﬁnal step, all possible
multivariable models of eight genes from 21 potentially important genes
were ﬁt to the training data (203,490multivariable models). The top 100
models were ranked by the concordance index and the highest time-
dependent AUC (tdAUC) and the ﬁnal model was chosen accordingly. A
risk score was calculated for each patient using the estimated regression
coefﬁcients from the training set.
2.7. Validation
The parameter estimates from the locked ﬁnal model were applied to
the testing set and a risk score was computed for every patient. The per-
formance of the ﬁnalmodel was assessed by computing the tdAUC. In ad-
dition, the tdAUC was computed for the eight gene model and for the
model containing only the Memorial Sloan Kettering Cancer Center
(MSKCC) clinical risk factors. The 95% CI for the tdAUC was computed
using the bootstrapped approach. The ﬁnal model was validated with
the risk score as a continuous variable. Tertiles based on the training set
were identiﬁed and applied to the risk score in the testing set. Patients
were grouped into low, intermediate or high-risk groups. The ﬁnal
model was validated by one of the authors (SH) who did not have access
to the training set. The Kaplan-Meier product-limit method was used to
estimate the overall survival distribution by the different risk groups
and the log-rank statisticwas used to test if the three-risk groupshavedif-
ferent survival outcomes. All statistical analyses for model development
and validation were performed using the R package.
2.8. Funding Support
Research reported in this publication was supported by the National
Cancer Institute of the National Institutes of Health under Award Num-
bers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials
in Oncology), CA31946, CA33601, R01CA133072, U01CA157703 and
R01CA155296. The content is solely the responsibility of the authors
and does not necessarily represent the ofﬁcial views of the NationalInstitutes of Health. The funders had no role in study design, data collec-
tion, data analysis, interpretation, and writing of the report.3. Results
CALGB 90206 enrolled 732 patients in the United States and Canada
between October 2003 and July 2005. The primary outcomes from the
treatment trial have been previously reported (Rini et al., 2008, 2010).
Fig. 1 presents the REMARK diagram. Consents for use of tissue for correl-
ative studieswere obtained from92% (676/732) of patients. The eligibility
for the parent trial required primary tumor tissue to be available. Howev-
er, tissue submission was not required for patients to start treatment.
Parafﬁn-embedded tumor blocks or unstained slides were received for
395 patients. All tissues were H&E stained and centrally reviewed by a
single GU pathologist (J.S.) The ﬁnal analysis was based on 324 patients
with available specimens.
Baseline patient characteristics are summarized in Table 1 for the
training and testing sets. The baseline clinical characteristics for patients
in the training and testing sets were comparable and similar to that of
the entire cohort enrolled on CALGB 90206 with a few exceptions.
Given that most tumor tissue came from cytoreductive nephrectomies,
the percent of patients having nephrectomywas higher in study subjects
(99% vs 73%).
Using the training set (n = 221), all 424 genes were evaluated in the
proportional hazards models in predicting OS. Univariate analysis for the
424 genes using the entire cohort of 324 subjects is presented in Supple-
mental Table 2. The top 21 prognostic genes are presented in Table 2.
These genes with q-value b0.05 were considered as candidate genes in











Median age, years 62 61 63 62
(25th, 75th percentile) (56–70) (55–69) (56–71) (55–70)
Gender (%)
Male 267 (70) 152 (69) 69 (67) 505 (69)
Female 112 (30) 69 (31) 34 (33) 227 (31)
Nephrectomy (%) 276 (73) 218 (99) 102 (99) 620 (85)
ECOG performance status (%)
0 122 (33) 92 (42) 36 (35) 259 (36)
1 225 (60) 112 (51) 58 (56) 414 (57)
2 27 (7) 14 (6) 8 (8) 50 (7)
Unknown 5 (0) 3 (1) 1 (1) 9
Common Sites of Metastases⁎ (%)
Lung 248 (66) 165 (75) 75 (73) 507 (69)
Lymph node 130 (34) 89 (40) 29 (28) 259 (35)
Bone 32 (33) 59 (27) 22 (21) 213 (29)
Liver 95 (25) 32 (14) 15 (15) 147 (20)
Number of Risk Factors⁎⁎ (%)
0 (favorable) 101 (27) 61 (28) 21 (20) 192 (26)
1–2 (intermediate) 231 (61) 144 (65) 74 (73) 465 (64)
N= 3 (poor) 47 (12) 16 (7) 8 (8) 75 (10)
⁎ Not mutually exclusive.
⁎⁎ MSKCC adverse clinical risk factors.
1817H.L. Kim et al. / EBioMedicine 2 (2015) 1814–1820values are provided. Lower ΔΔCT's corresponds to higher expression
levels, therefore HRs b1 indicate higher expression level and decreased
risk of death.
3.1. Multivariable Model
Using LASSO 8 genes were identiﬁed. Therefore, 8 geneswere deter-
mined as the optimal size for the ﬁnal model and all possible models of
eight genes out of 21 signiﬁcant geneswereﬁt. For illustrative purposes,
the Kaplan-Meier plots are provided for each of the eight genes that
were included in theﬁnalmodel. The genes are dichotomized by the ob-
served medians into high and low expression groups (Supplemental
Fig. 1). In the parent clinical trial, the number of MSKCC clinical risk fac-
tors was used as a stratiﬁcation factor in the randomization. Therefore,
MSKCC clinical risk factors were included in the ﬁnal multivariable
model (Table 3). In the training set, the tdAUC for the ﬁnal 8-gene
model with the MSKCC risk factors was 0.71 (95% CI = 0.59–0.73).
For CRYL1, PCNA and CDK1, decreased expression levels were associated
with worse OS; however, for TRAF2, USP6NL, CEP55,HGF and HSD17B10,Table 2
Top 21 prognostic genes in the training set⁎.
Genes HR⁎⁎ CI⁎⁎ p-value q-value
MCM2 0.7 (0.60–0.82) b0.0001 0.00297
CCNB1 0.74 (0.64–0.86) b0.0001 0.01036
TOP2A 0.75 (0.64–0.87) 0.00015 0.01036
NPM3 0.74 (0.63–0.86) 0.00016 0.01036
CEP55 0.75 (0.64–0.87) 0.00025 0.01282
FSCN1 0.76 (0.65–0.88) 0.00036 0.0152
KIAA0101 0.76 (0.65–0.89) 0.00052 0.01912
CRYL1 1.3 (1.11–1.53) 0.00088 0.02507
CDK1 0.77 (0.65–0.90) 0.00098 0.02507
KIF23 0.78 (0.67–0.90) 0.00105 0.02507
L1CAM 0.78 (0.68–0.91) 0.00108 0.02507
TRAF2 0.78 (0.67–0.91) 0.00127 0.02582
ANLN 0.77 (0.65–0.90) 0.00131 0.02582
KLK1 0.77 (0.66–0.91) 0.0017 0.02968
HGF 0.78 (0.66–0.91) 0.00174 0.02968
USP6NL 0.79 (0.68–0.92) 0.00265 0.04073
PCNA 0.8 (0.69–0.93) 0.00286 0.04073
MELK 0.77 (0.65–0.92) 0.0029 0.04073
PRC1 0.78 (0.66–0.92) 0.00312 0.04073
POLR2B 0.8 (0.69–0.93) 0.00322 0.04073
HSD17B10 0.8 (0.69–0.93) 0.00334 0.04073
⁎ Genes in our ﬁnal prognostic model are in bold.
⁎⁎ HR, hazard ratio; CI, 95% conﬁdence interval.the inverse association was observed. The ﬁnal model was assessed for
calibration (internal validation). The predicted probabilities at 18 (me-
dian OS in the clinical trial)-, and 24-months from themodelwere close
to the observed probability of survival (Supplement Fig. 2).
3.2. Testing Set
Using the ﬁnal model, risk score was highly predictive of OS with a
tdAUC = 0.72 (95% CI = 0.66–0.78). The testing set was divided into
equal thirds to generate cutoffs for low, intermediate, and high risk
groups. Median OSs were 38 (95% CI = 26-not reached), 21 (95% CI =
14–32) and 13 (95% CI = 9–19) months, respectively (p b 0.001, Fig.
2a). For comparison, the 8-gene model without the MSKCC clinical
risk factors was similarly applied to the testing set (Fig. 2b) and had a
tdAUC of 0.69 (95% CI = 0.62–0.72). Fig. 2c presents the Kaplan-Meier
survival curves for risk groups based on number of MSKCC clinical risk
factors. It is noteworthy that the tdAUC for this model was only
0.61(95% CI = 0.54–0.69). Fig. 3 shows the AUC at 18 (Fig. 3a) and 24
months (Fig. 3b) for the three models. It is clear that the ﬁnal model
based on the 8 genes and the MSKCC clinical risk factors is superior to
the model with MSKCC clinical risk factors alone.
3.3. Stability Analysis
Mutations in individual renal tumors are highly heterogeneous
(Gerlinger et al., 2012, 2014). Therefore, to ensure the stability of our
gene signature, the expression of the 424 candidate genes were mea-
sured from two random sites using 12 primary clear cell RCCs fromTable 3
Prognostic model for predicting overall survival: training set.*
HR⁎ 95% CI⁎ p-value
CRYL1 1.428 (1.188, 1.716) 0.0001
TRAF2 0.806 (0.688, 0.945) 0.0079
USP6NL 0.914 (0.751, 1.111) 0.0101
CEP55 0.772 (0.634, 0.940) 0.0246
HGF 0.918 (0.761, 1.107) 0.1818
PCNA 1.167 (0.930, 1.464) 0.3657
CDK1 1.093 (0.870, 1.372) 0.3688
HSD17B10 0.793 (0.648, 0.971) 0.4449
1–2 RF⁎⁎ vs. 0 1.317 (0.939, 1.849) 0.111
N= 3 RF vs. 0 2.596 (1.467, 4.594) 0.001
⁎ HR, hazard ratio; CI, 95% conﬁdence interval.
⁎⁎ RF, MSKCC Adverse Clinical Risk Factors.
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deviations for each RCC. The stability measure for each gene was the
median of the 12 standard deviations. K-means clustering (K = 2)
wasused to determine a threshold (0.78) for dividing the genes into sta-
ble and unstable genes based on the stability measure (Fig. 4). Of the
424 genes, 83 genes were considered unstable. All 8 genes in our ﬁnal
model were conﬁrmed to be stable. In a post-hoc analysis, we repeated
our model building approach using stable genes only, and achieved a
test AUC of 0.72, just below our locked model. This is in part due to
the fact that the most signiﬁcant genes in univariate analysis tended
to be stable genes.
4. Discussion
Approximately one-third of patients newly diagnosed with RCC
have metastatic disease, and after treatment for localized RCC, 25–50%
of patients will suffer metastatic recurrence. The survival for individual
patients can vary widely. Patients can be stratiﬁed into risk groups
based on readily available clinical parameters such as performance sta-
tus, serum lactate dehydrogenase, hemoglobin, serum calcium, and
length of time between initial diagnosis and treatment (Motzer et al.,
2002). The number of MSKCC adverse clinical risk factors was used to
stratify the randomization for the parent clinical trial of this study,
CALGB 90206. Unfortunately, MSKCC adverse clinical risk factors only
had modest prognostic ability in our population with a tdAUC of 0.61,
demonstrating the need for developing predictive markers with higher
precision.
This study developed a multimarker prognostic signature from a
large multicenter phase III, randomized clinical trial in RCC in which el-
igibility was clearly deﬁned and outcomes rigorously recorded. In addi-
tion to recruiting a diverse range of patients, a multicenter study is less
susceptible to systematic bias introduced by institution-speciﬁc proce-
dures for tissuehandling and storage. Importantly, the prognostic signa-
ture was obtained using formalin-ﬁxed, parafﬁn-embedded tumors,
which are routinely collected and stored in all pathology departments.
For clear cell RCC, tumor tissue is routinely available from cytoreductive
nephrectomy or diagnostic biopsy. To the best of our knowledge, there
are no prior reports of a multimarker molecular signature developed
from a multicenter, phase III clinical trial of RCC.
CALGB 90206 randomized patients with newly diagnosed clear cell
RCC to IFN or IFN plus bevacizumab (Rini et al., 2008). The primary end-
point was overall survival, and secondary endpoints were progression
free survival and safety. The majority (85%) of patients underwent a
cytoreductive nephrectomy, and 90% had favorable or intermediate
prognosis based on number of MSKCC adverse clinical risk factors. At
the interim analysis, the median PFS was 5.2 months in the IFN group
and 8.5 months in the IFN plus bevacizumab group (p b 0.0001). How-
ever, no statistically signiﬁcant difference in OS was observed between
the two groups. The median OS was 17.4 months in the IFN group and
18.3 months in the combination arm (Rini et al., 2010). Furthermore,
subset analysis failed to identify any clinical variable associated with
treatment response. Therefore, no clinical variable other than MSKCC
adverse clinical risk factors were included in our ﬁnal model.
An important limitation of prior biomarkers studies is that they in-
cluded all stages of RCC (Takahashi et al., 2001; Sultmann et al., 2005;
Kosari et al., 2005; Jones et al., 2005; Zhao et al., 2006; Cancer Genome
Atlas ResearchN, 2013; Brannon et al., 2010), limiting their applicability
to patients with metastatic disease. However, many of these studies
used an unbiased, genome-wide approach to discovery of prognostic
markers, and provided a wealth of candidate gene expression markersFig. 2.Kaplan–Meier survival curves for prognostics models. (a) Final model containing 8-
genes plus MSKCC clinical risk factors. (b) 8-gene-only prognostic model. (a &
b) Multivariable model developed using the training set was used to assign risk scores
to the testing set. Cutoffs for risk groups were deﬁned by dividing the training set into
tertiles. (c) Risk groups deﬁned by number of MSKCC clinical risk factors.
Fig. 3.AUC plots at 18-months (a) and 24months (b). The green line represents the ﬁnalmodel, blue line is themodel with 8 genes, and the red line is theMKSCC clinical risk factors only.
1819H.L. Kim et al. / EBioMedicine 2 (2015) 1814–1820for us to evaluate. An increased understanding of pathways and
mechanisms driving clear cell RCC provided additional candidate
markers. In univariate analysis, we found that 21 of the candidate
biomarkers were signiﬁcant predictors of OS using q b 0.05 (Table 2
and Supplemental Table 2). These results are validation of prior
discovery studies of prognostic markers.
Our multivariable analysis identiﬁed an 8-gene model of OS.
Following VHL inactivation, PBRM1 is the second major gene in
ccRCC, with truncating mutations in 41% of cases (Varela et al.,
2011). Genes in pathways deregulated following PBRM1 knockdown
in RCC cell lines were included as candidate genes in this study. In
our ﬁnal prognostic model, 4 genes (CRYL1, HSD17B10, CEP55 and
HGF) were PBRM1 related genes; 3 (CRYL1, HSD17B10 and CEP55)
were also differentially expressed when comparing ccRCC to
normal kidney (Tun et al., 2010). HGF, which binds the proto-
oncogene c-MET, has been linked to invasiveness and VHL inactiva-
tion in ccRCC (Horie et al., 1999; Koochekpour et al., 1999;
Harshman and Choueiri, 2013). Both TRAF2 (Vasselli et al., 2003)
and USP6NL (Zhao et al., 2006) were previously identiﬁed as
prognostic genes is microarray-based studies of RCC. PCNA was in-
cluded as a candidate gene because it is a classic marker of prolifera-
tion and has been previously associated with RCC prognosis
(Nogueira and Kim, 2008). CDK1, a cell cycle regulator, was includedFig. 4. Evaluation of tumor heterogeneity. The tumor was sampled in two separate areas
and gene expressions were determined by qPCR. Heterogeneity was deﬁned as the medi-
anof standarddeviationsdetermined from sampling each tumor twice. A threshold of 0.78
for unacceptable heterogeneity (black circles)was determined using the K-means cluster-
ing algorithm with k = 2.as a candidate gene because it was previously reported to predict re-
sponse to antiangiogenic and epidermal growth factor targeted ther-
apy in RCC (Tsavachidou-Fenner et al., 2010). When generating our
prognostic signature, genes were favored that provided independent
and non-redundant prognostic information. Therefore, it is not sur-
prising that our 8 genes have been associated with a wide range of
functions important to cancer progression such as proliferation
(CEP55, PCNA, CDK1), apoptosis (TRAF2), metabolism (CRYL1,
HSD17B10) and invasion (HGF) (http://www.ncbi.nlm.nih.gov/
gene, 2015).
The genetic heterogeneity of RCC is well documented (Gerlinger
et al., 2012, 2014). However, the clonal evolutionary tree has a
common “trunk” that links all genomic mutations. In addition,
there are common histologic features that pathologists use to classify
renal tissue as RCC. Therefore, it is reasonable to expect that there are
markers, particularly expression markers that directly reﬂect the
phenotype of RCC. To generate a signature that was less sensitive to
sampling artifacts produced by tumor heterogeneity, we performed
a separate analysis using untreated primary tumors from metastatic
clear cell RCC patients that were sampled in two different areas.
Genes with heterogeneous expression within individual patients
were excluded from consideration in our multimarker models.
There are several strengths of the present analysis. First, the trial had
a large number of tissue specimen available. Second, the datawere from
a randomized multi-institutional phase III trial. Results of multicenter
studies are convincing because tissues are less susceptible to systemic
bias resulting from institution-speciﬁc tissue-handling protocols and
are more likely to be representative. The parent trial clearly deﬁnes
the patient cohort for which the signature can be applied. Furthermore,
patient treatment and follow-up have been rigorously recorded, with
oversight from a highly developed coordinating center.
An important limitation of the study is the absence of an external
validation cohort. What remains unresolved is whether tissue
handling introduced systematic bias or that the assay is reproducible
by other investigators. However, the tissue was received, stored and
released by the CALGB pathology central ofﬁce, which has extensive
experience with biobanking for clinical trials. The qPCR assay is well
established and robust, and routinely used in commercial laboratories.
Future studies should further validate our prognostic signature and
establish its clinical utility to impact patient outcome by improving
survival or deceasing treatment-related morbidity. Additional studies
can qualify the signature for use with additional, related cohorts of
RCC such as patients treated for clinically localized RCC who remain at
high risk for recurrence.
1820 H.L. Kim et al. / EBioMedicine 2 (2015) 1814–18205. Conclusion
A molecular prognostic signature based on 8 genes and MSKCC ad-
verse clinical risk factors was developed and tested using tissue from a
phase III trial and predicts OS in patients with metastatic clear cell RCC.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.09.012.
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